

NICE Technology Appraisals About Medicines: Formulary Adherence

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE	
			Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2016-17				
TA437 - Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy	22/03/2017	NICE was unable to make a recommendation about the use in the NHS of ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy because no evidence submission was received from Janssen-Cilag, but will review this decision if the company decides to make a submission.	No	Appraisal terminated
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (TA436)	22/03/2017	NICE was unable to make a recommendation about the use in the NHS of bevacizumab for treating epidermal growth factor receptor mutation-positive non-small-cell lung cancer because no evidence submission was received from Roche, but will review this decision if the company decides to make a submission.	No	Appraisal terminated
Tenofovir alafenamide for treating chronic Hepatitis B (TA435)	22/03/2017	NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was received from Gilead, but will review this decision if the company decides to make a submission.	No	Appraisal terminated
Elotuzumab for previously treated multiple myeloma (TA434)	22/03/2017	NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was received from Bristol-Myers Squibb, but will review this decision if the company decides to make a submission	No	Appraisal terminated
Apremilast for treating active psoriatic arthritis (TA433)	22/02/2017	Apremilast , alone or in combination with disease-modifying antirheumatic drugs (DMARDs), is recommended as an option for treating active psoriatic arthritis in adults	Yes	
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)	22/02/2017	Everolimus is recommended within its marketing authorisation as an option for treating advanced renal cell carcinoma that has progressed during or after treatment with vascular endothelial growth factor targeted therapy, only if the company provides it with the discount agreed in the patient access scheme.	Yes	
Mepolizumab for treating severe refractory eosinophilic asthma (TA431)	25/01/2017	Mepolizumab , as an add-on to optimised standard therapy, is recommended as an option for treating severe refractory eosinophilic asthma in adults	No	Not applicable to CWH
Sofosbuvir-velpatasvir for treating chronic hepatitis C (TA430)	25/01/2017	Sofosbuvir-velpatasvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1, only if the company provides the drug with the discount agreed in the simple discount agreement.	Yes	
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or	25/01/2017	Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults	Yes	
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)	11/01/2017	Pembrolizumab is recommended as an option for treating locally advanced or metastatic PD-L1-positive non-small-cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK]-positive tumour),	Yes	
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)	11/01/2017	Pomalidomide , in combination with low-dose dexamethasone, is recommended as an option for treating multiple myeloma in adults at third or subsequent relapse; that is, after 3 previous treatments including both lenalidomide and bortezomib, only when the company provides pomalidomide with the discount agreed in the patient access scheme.	Yes	
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)	21/12/2016	Imatinib is recommended as an option for untreated, chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults	Yes	
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)	21/12/2016	Dasatinib and nilotinib are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults	Yes	
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)	21/12/2016	Pertuzumab , in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with human epidermal growth factor receptor 2 (HER2)-positive breast cancer; that is, in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of	Yes	
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA422)	21/12/2016	Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults,	Yes	
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)	21/12/2016	Crizotinib is recommended, within its marketing authorisation, as an option for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.	Yes	

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)	21/12/2016	Everolimus , in combination with exemestane, is recommended within its marketing authorisation, as an option for treating advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women without symptomatic visceral disease that has recurred or progressed after a non-steroidal aromatase inhibitor. Everolimus is recommended only if the company provides it with the discount agreed in the patient access scheme.	Yes	
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)	14/12/2016	Ticagrelor , in combination with aspirin, is recommended within its marketing authorisation as an option for preventing atherothrombotic events in adults who had a myocardial infarction and who are at high risk of a further event.	Yes	
Apremilast for treating moderate to severe plaque psoriasis (TA419)	23/11/2016	Apremilast is recommended as an option for treating chronic plaque psoriasis in adults whose disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and ultraviolet-A light), or when these treatments are contraindicated or not tolerated	Yes	
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)	23/11/2016	Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a	Yes	
Nivolumab for previously treated advanced renal cell carcinoma (TA417)	23/11/2016	Nivolumab is recommended, within its marketing authorisation, as an option for previously treated advanced renal cell carcinoma in adults, when the company provides nivolumab with the discount agreed in the patient access scheme.	Yes	
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)	26/10/2016	Osimertinib is recommended as an option for use within the Cancer Drugs Fund for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed	Yes	
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)	26/10/2016	Certolizumab pegol , in combination with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor-alpha (TNF-alpha) inhibitor	Yes	
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)	26/10/2016	Cobimetinib in combination with vemurafenib is not recommended within its marketing authorisation for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.	No	Not recommended
Elbasvir-grazoprevir for treating chronic hepatitis C (TA413)	26/10/2016	Elbasvir-grazoprevir is recommended, within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults, as specified in table 1, only if the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit	Yes	
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)	28/09/2016	Radium-223 dichloride is recommended as an option for treating hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases in adults	No	Not applicable to CWH
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)	28/09/2016	Necitumumab , in combination with gemcitabine and cisplatin, is not recommended within its marketing authorisation for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy.	No	Not recommended
Talinogene laherparepvec for treating unresectable metastatic melanoma (TA410)	28/09/2016	Talinogene laherparepvec is recommended, in adults, as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs	No	Not applicable to CWH
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)	28/09/2016	Aflibercept is recommended as an option within its marketing authorisation for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion, only if the company provides aflibercept with the discount agreed in the patient	Yes	
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)	28/09/2016	Pegaspargase , as part of antineoplastic combination therapy, is recommended as an option for treating acute lymphoblastic leukaemia in children, young people and adults only when they have untreated newly diagnosed disease.	No	Not applicable to CWH
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)	28/09/2016	Secukinumab is recommended, within its marketing authorisation, as an option for treating active ankylosing spondylitis in adults whose disease has responded inadequately to conventional therapy (non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors)	Yes	
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)	28/09/2016	Crizotinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung	Yes	
Trifluridine-tipiracil for previously treated metastatic colorectal cancer (TA405)	24/08/2016	Trifluridine-tipiracil is recommended, within its marketing authorisation, as an option for treating metastatic colorectal cancer	Yes	

Degarelix for treating advanced hormone-dependent prostate cancer (TA404)	24/08/2016	Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016.	Yes	
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)	24/08/2016	Ramucirumab , in combination with docetaxel, is not recommended within its marketing authorisation for treating locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed after platinum-based chemotherapy.	No	Not recommended
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)	24/08/2016	Pemetrexed is recommended as an option for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer	Yes	
Bosutinib for previously treated chronic myeloid leukaemia (TA401)	24/08/2016	Bosutinib is recommended as an option, within its marketing authorisation, for chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults	Yes	
Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)	27/07/2016	Lumacaftor-ivacaftor is not recommended for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	No	Not recommended
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)	27/07/2016	Azacitidine is not recommended for treating acute myeloid leukaemia with more than 30% bone marrow blasts in people of 65 years or older who are not eligible for haematopoietic stem cell transplant.	No	Not recommended
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)	27/07/2016	Nivolumab in combination with ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma.	Yes	
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)	22/06/2016	Adalimumab is recommended as an option for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.	Yes	
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)	22/06/2016	Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia.	Yes	
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)	22/06/2016	Evolocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia.	Yes	
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)	22/06/2016	Ceritinib is recommended as an option for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have previously had crizotinib.	Yes	
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)	22/06/2016	Trametinib in combination with dabrafenib is recommended as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation	Yes	
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)	22/06/2016	Belimumab is recommended as an option as add-on treatment for active autoantibody-positive systemic lupus erythematosus in adults	No	Not applicable to CWH
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)	25/05/2016	Canagliflozin , dapagliflozin and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control.	Yes	
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)	25/05/2016	Cabazitaxel in combination with prednisone or prednisolone is recommended as an option for treating metastatic hormone-relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy.	Yes	
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)	27/04/2016	Sacubitril valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction.	Yes	
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)	26/04/2016	Paclitaxel as monotherapy or in combination with platinum, and pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy or in combination with platinum, are recommended as options for treating recurrent ovarian cancer. Trabectedin in combination with PLDH, gemcitabine in combination with carboplatin, and topotecan are not recommended for treating the first recurrence of platinum-sensitive ovarian cancer. Topotecan is also not recommended for treating recurrent platinum-resistant or platinum-refractory ovarian	No	Not recommended and Not applicable to C&W
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)	26/04/2016	Abiraterone in combination with prednisone or prednisolone is recommended as an option for treating metastatic hormone-relapsed prostate cancer.	Yes	